αSynuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson’s disease by Pozo Devoto, Victorio Martin et al.
1Scientific RepoRts | 7: 5042  | DOI:10.1038/s41598-017-05334-9
www.nature.com/scientificreports
αSynuclein control of 
mitochondrial homeostasis 
in human-derived neurons is 
disrupted by mutations associated 
with Parkinson’s disease
Victorio Martin Pozo Devoto1,2, Nicolas Dimopoulos3, Matías Alloatti1, María Belén Pardi5, 
Trinidad M. Saez1,4, María Gabriela Otero1, Lucas Eneas Cromberg1, Antonia Marín-Burgin5, 
Maria Elida Scassa3, Gorazd B. Stokin2, Alejandro F. Schinder6, Gustavo Sevlever  3 & Tomás 
Luis Falzone1,4
The etiology of Parkinson’s disease (PD) converges on a common pathogenic pathway of mitochondrial 
defects in which α-Synuclein (αSyn) is thought to play a role. However, the mechanisms by which αSyn 
and its disease-associated allelic variants cause mitochondrial dysfunction remain unknown. Here, we 
analyzed mitochondrial axonal transport and morphology in human-derived neurons overexpressing 
wild-type (WT) αSyn or the mutated variants A30P or A53T, which are known to have differential 
lipid affinities. A53T αSyn was enriched in mitochondrial fractions, inducing significant mitochondrial 
transport defects and fragmentation, while milder defects were elicited by WT and A30P. We found that 
αSyn-mediated mitochondrial fragmentation was linked to expression levels in WT and A53T variants. 
Targeted delivery of WT and A53T αSyn to the outer mitochondrial membrane further increased 
fragmentation, whereas A30P did not. Genomic editing to disrupt the N-terminal domain of αSyn, 
which is important for membrane association, resulted in mitochondrial elongation without changes 
in fusion-fission protein levels, suggesting that αSyn plays a direct physiological role in mitochondrial 
size maintenance. Thus, we demonstrate that the association of αSyn with the mitochondria, which 
is modulated by protein mutation and dosage, influences mitochondrial transport and morphology, 
highlighting its relevance in a common pathway impaired in PD.
Parkinson’s disease (PD), the second most prevalent neurodegenerative disorder, is pathologically characterized 
by progressive neuronal loss and the accumulation of eosinophilic intracellular inclusions, termed Lewy bod-
ies1. The major component of these inclusions is α-Synuclein (αSyn)2, the first protein linked with dominant 
familial PD3. So far, more than 20 loci are known to contribute to familial PD, many of which are implicated 
in the regulation of mitochondrial homeostasis4, 5. Although genetic mutations account for a small proportion 
of PD cases, there is both pathological and pharmacological evidence to support a key role for mitochondrial 
dysfunction in the progression of sporadic PD6, 7. Recent evidence supports a direct link between αSyn function 
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and mitochondrial pathologies8–10; however, the precise molecular mechanisms by which αSyn may induce mito-
chondrial defects remain unclear.
Mitochondrial-related proteins govern both fusion-fission rates and transport, leading to a direct effect on 
mitochondrial size and homeostasis. Impairments in these processes have been associated with many neuro-
degenerative diseases11. In PD, familial mutations in PTEN-induced putative kinase 1 (PINK1), Parkin, DJ-1, 
leucine-rich repeat kinase (LRRK), ATP13A2, and recently, vacuolar protein sorting-associated protein 35 
(VPS35) have been found to control mitochondrial size and transport through interaction with fusion-fission 
proteins and molecular motors12–18.
Patients carrying αSyn gene (SNCA) triplications display earlier disease onset compared with patients carry-
ing SNCA duplications, indicating that intracellular levels of αSyn determine the development of pathology in a 
dose-dependent manner19, 20. In addition to the aggregation properties of αSyn, in vitro membrane-binding stud-
ies suggest that αSyn adopts an α-helix conformation at the N-terminal domain when interacting with lipids21. 
Disruption of this conformation via the A30P αSyn mutation leads to a reduced affinity for lipids, whereas the 
A53T αSyn mutation produces the opposite effect22. This difference in lipid affinity correlates with an earlier onset 
and more severe manifestations in patients with A53T mutation, while A30P induces late age onset and milder 
symptoms23, 24. However, it is unclear how these two distinct mutations, which have opposing effects on mem-
brane affinity, result in mitochondrial defects.
Differential associations of αSyn mutants with mitochondria have been proposed, with some studies report-
ing the presence of αSyn inside the mitochondria, whereas others report localization to the outer mitochondrial 
membrane (OMM)25–27. Interestingly, changes in mitochondrial morphology were described as common fea-
tures in several animal models of αSyn mutation or overexpression28–30 as well as in human cellular models26, 31. 
Moreover, mitochondrial fission has been linked to αSyn function29, 31. However, robust evidence demonstrating 
a direct regulation of mitochondrial size by αSyn-dependent mechanisms in human neurons is lacking.
Here, we sought to determine whether αSyn protein plays a direct role in the regulation of mitochondrial 
homeostasis, both under physiological and pathological conditions, in a human cell model. Using human neurons 
derived from embryonic stem cells (hESC) or induced pluripotent stem cells (hiPSC), we studied mitochondrial 
axonal transport and morphology in the presence of overexpressed wild-type or mutant αSyn. αSyn overexpres-
sion was found to induce mitochondrial transport defects and fragmentation. Forced delivery of αSyn to the 
OMM resulted in a strong reduction in mitochondrial size, suggesting that αSyn variants can induce differential 
effects in a common pathological pathway. Moreover, disruption of the α-helix conformation in the N-terminal 
domain of αSyn in human neurons uncovered a physiological function for endogenous αSyn in the maintenance 
of neuronal mitochondrial size. Our findings, in a relevant human neuronal model, demonstrate a key role for 
αSyn in the development of mitochondrial pathology associated with PD, and highlight a potential target for early 
therapeutic intervention prior to neuronal loss and clinical manifestation of PD.
Results
αSyn overexpression in hESC-derived neurons. To study the physiological and pathological roles of 
αSyn in mitochondrial dynamics within the context of human PD, we obtained enriched, polarized, and func-
tional human neurons derived from hESC according to a previously described protocol (Figs 1A–F, S1A)32. The 
differentiation stages from pluripotent colonies to terminally differentiated neurons were evaluated by quan-
tification of mRNA and protein expression levels. Pluripotent markers (OCT4, SOX2, Nanog) were present in 
the undifferentiated stages (Figure S1B) and downregulated at final differentiation, whereas neuronal markers, 
including βIII tubulin, pan-NCAM, and tyrosine hydroxylase (TH), appeared upregulated in differentiated neu-
rons (Figs 1D, S1B and S1C). Imaging of differentiated neurons indicated conspicuous expression of βIII tubulin 
but weak expression of nestin (Fig. 1A). A diffuse cytosolic pattern of endogenous αSyn was observed, with punc-
tate distribution among neurites labeled with p-Tau (Fig. 1B and C). Furthermore, enriched neuronal cultures 
(55.17%+/− 2.2; Figure S3A) showed a time-dependent maturation of tau isoform splicing33 and progression of 
electrophysiological profiles, including repetitive spiking and increased amplitude of voltage-dependent Na+ and 
K+ currents (Figs 1E,F and S2), recapitulating key hallmarks in neuronal development. To examine the role of 
αSyn in mitochondria, neurons were transfected with pLV-CMV-αSyn vectors encoding wild-type (WT) αSyn 
or the familial PD mutations, A30P or A53T (Fig. 1G). Based on electrophysiological profile and robust neu-
ronal marker expression indicative of neuronal differentiation, transfections were performed on day 14 in vitro 
(DIV14). Increased expression of αSyn was observed in transfected p-Tau-labeled neurons (Fig. 1H). To distin-
guish transfected αSyn from endogenous protein, neurons co-transfected with vectors encoding EGFP and WT, 
A30P, or A53T αSyn were analyzed by immunofluorescence (Fig. 1I). Quantification of αSyn fluorescent inten-
sity revealed a 2- to 3-fold increase in αSyn signal in transfected neurons (WT, A30P, or A53T) compared with 
endogenous αSyn expression (Fig. 1J), characterizing αSyn overexpression profiles in our neuronal model. αSyn 
overexpression was further validated by flow cytometric analysis of neurons transfected with vectors encoding 
mCherry and WT, A30P, or A53T αSyn (Figure S3B). No neurotoxic effects were observed in response to overex-
pression of any of the αSyn variants (Figs 1K, S3C).
αSyn overexpression induces mitochondrial axonal transport defects. Neuronal homeostasis 
is reliant on the appropriate subcellular distribution of organelles, including mitochondria18, 34. αSyn expres-
sion has been shown to influence axonal transport, which in turn affects mitochondrial fusion-fission rates13, 
17, 35, 36. To test the effects of αSyn overexpression on axonal transport of mitochondria in our human-derived 
neuronal model, we performed live-imaging analysis of cells co-transfected with a vector driving GFP fused 
to a mitochondrial-targeting sequence (mito-GFP) in addition to WT, A30P, or A53T αSyn-expressing vectors 
(Figs 2A, S4A). Time-lapse movies from transfected axons were transformed to kymographs to track and quan-
tify mitochondrial movement (Fig. 2B, Movies M1–4). Mitochondrial transport from WT, A30P, or A53T αSyn 
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Figure 1. αSyn overexpression in functional hESC-derived neurons. (A–F) Human neuronal culture 
characterization. (A) High expression of the neuronal marker, β3-tubulin, and low expression of the precursor 
marker, nestin (Scale bar, 100 μm). (B) Endogenous αSyn cytosolic localization. Nuclei stained with Hoechst 
(blue). Scale bar, 100 μm. (C) αSyn localization is enriched within neuronal processes (p-Tau). Scale bar, 
20 μm. (D) qPCR quantification at day 41 of the differentiation protocol showing mRNA expression for 
stemness (Oct4, Nanog), neural markers (Pax6, Nestin), and specific neuronal markers (Tuj1, TH) relative to 
undifferentiated hESC (mean ± SEM, n = 4 independent experiments). (E) Representative traces of spiking 
evoked by stepwise increases of current from 0 to 40 pA, incremented by 10 pA. Cells were kept at −60 mV in 
current clamp. (F) Representative traces of Na+ and K+ voltage-dependent currents evoked by depolarizing 
voltage steps, incremented every 10 mV. Cells were voltage clamped at −70 mV. Inset shows higher temporal 
resolution. (G–J). Human neurons overexpressing αSyn. (G) αSyn immunofluorescent staining in transfected 
neurons (asterisk), non-transfected neurons (arrows), and non-αSyn-expressing cells (arrowhead) at DIV14 
cultures. Scale bar, 50 μm. (H) Neurons (p-tau) transfected with αSyn display increased levels of expression by 
immunofluorescence. Scale bar, 50 μm. (I and J) αSyn immunofluorescent staining in neurons co-transfected 
with EGFP and control (empty), WT, A30P, or A53T αSyn (asterisks). Scale bar, 50 μm. Intensity measurements 
of αSyn staining in the different conditions. Data represented as median plus interquartile range. Kruskal-
Wallis ANOVA (p < 0.05). (n = 80 neurons per condition from 2 independent experiments). (K) Average cell 
ratio performed to identify neuron survival upon αSyn expression in 1, 3 and 5 days post-transfection (DPTX). 
Ratio obtained by dividing αSyn positive neurons (overexpressing above threshold in Fig. S3C) by total 
EGFP + neurons (above and below αSyn threshold) (n = 20 images per condition, more than 5 neurons by field 
from 2 independent experiments). See also Figures S1, S2 and S3.
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Figure 2. Mitochondrial axonal transport is differentially affected by αSyn variants. (A) Neuron co-transfected 
with mito-GFP and WT αSyn. Scale bar, 100 μm. (B) Mitochondria (mito-GFP) in axonal projections from a 
transfected neuron used for live-imaging, magnified projection, and kymograph plotting. Kymograph obtained 
from a 150-s time-lapse movie at 3-s intervals. Left panel scale bar: 30 μm, horizontal: 10 μm. (C) Representative 
kymographs for αSyn transfected neurons obtained from supplementary movies (Sup Movies 1–4). Scale bar, 
10 μm. (D) Overall anterograde, retrograde, or stationary axonal mitochondrial proportion does not change upon 
αSyn overexpression. Data represented as median plus interquartile range (n > 50 axons per condition from 10 
independent experiments). Kruskal-Wallis ANOVA for each type of movement (p > 0.05). (E) Anterograde to 
retrograde moving time differences observed in control mitochondria are lost in A53T transfected neurons but 
not in WT and A30P αSyn. (F) Anterograde to retrograde mean segmental velocity differences are lost in WT and 
A53T αSyn-transfected neurons (n = 60 per condition from 10 independent experiments). (G) Anterograde to 
retrograde mitochondrial flux (traveled distance per mitochondria normalized to acquisition time (nm/seg)) is 
impaired in all αSyn overexpression conditions compared with control (n = 60 per condition from 10 independent 
experiments). Data represented as median plus interquartile range. Mann-Whitney U test between anterograde 
and retrograde movements for each parameter. ***p < 0.001, **p < 0.01, *p < 0.05. (H) αSyn overexpression 
does not impair mitochondrial membrane potential. Mitochondrial membrane potential was analyzed in 
transduced DIV14 neurons using JC1. Low and high (green and red emission, respectively) membrane potential 
was quantified by fluorescence intensity and Manders’ colocalization coefficient was calculated. Mitochondrial 
ionophore FCCP was used as positive control. Data represented as mean ± SEM (n = 7 independent experiments). 
Two-way ANOVA followed by Sidak’s corrected comparison of Manders’ coefficient for each condition, 
***p > 0.001. Scale bar, 200 μm. See also Movies M1–M4, Figure S4.
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(Fig. 2C) showed similar overall anterograde, stationary, and retrograde mitochondrial proportions when com-
pared with control (mCherry-transfected) neurons (Fig. 2D). However, detailed analysis of mitochondrial kinet-
ics, by discriminating segmental velocities and time during movement (Fig. 2E and F), revealed a difference in 
control neurons, which displayed a significant bias to anterograde flux compared with retrograde flux (Fig. 2G). 
This asymmetry, which is important for maintenance of distal distribution of axonal mitochondria, was lost in 
αSyn-overexpressing cells (Fig. 2G). WT and A53T αSyn-overexpressing neurons showed similar anterograde 
and retrograde mitochondrial segmental velocities (Fig. 2F), and A53T αSyn overexpression also resulted in 
similar time spent moving in retrograde and anterograde directions (Fig. 2E). These results reveal impairments in 
mitochondrial flux in transfected axons, with the most pronounced effect in A53T αSyn-overexpressing neurons, 
indicating that αSyn overexpression leads to an imbalance in the distribution of mitochondria throughout the 
axon.
To test whether mitochondrial flux impairments are related to an αSyn effect on mitochondrial homeostasis, 
we assessed mitochondrial membrane potential in neurons transduced with WT, A30P, or A53T pLV-CMV-αSyn 
(Figs 2H, S4B). JC1, a mitochondrial probe that changes its emission wavelength when oligomerized under 
hyperpolarizing membrane potential, was used to assess mitochondrial function. Colocalization analysis using 
Manders’ correlation coefficient for red versus green intensities showed no significant changes in mitochondrial 
membrane potential in any of the αSyn-overexpressing neurons (Figs 2H and S4C). Our results indicate that 
axonal flux impairments observed upon αSyn overexpression are not caused by depolarization of the mitochon-
dria; thus, the effects seen are unlikely to be the result of short-term effects on mitochondrial health.
Axonal mitochondrial fragmentation in neurons overexpressing A53T αSyn. To test whether the 
changes in mitochondrial flux observed upon αSyn overexpression in human neurons promote mitochondrial 
fragmentation, as previously described in both cellular and animal systems28–31, we analyzed the morphology of 
axonal mitochondria after co-transfecting human-derived neurons with mito-GFP and αSyn vectors (Fig. 3A). 
Control, WT, and A30P αSyn-overexpressing neurons showed similar mean mitochondrial lengths per axon. 
However, transfection with A53T αSyn resulted in a significant decrease in mitochondrial length and an increased 
number of mitochondria per axon (Fig. 3A). To confirm this result, an immunofluorescent staining approach 
using mitochondrial cytochrome C oxidase I (COX-I) was performed in neurons transfected with EGFP, WT, 
A30P, or A53T αSyn vectors. Again, A53T αSyn overexpression resulted in a significant reduction in the size of 
axonal mitochondria while no changes were observed upon WT or A30P αSyn overexpression (Fig. 3B). In addi-
tion, total axonal mitochondria exhibited a significant size decrease in A53T and WT αSyn-transfected neurons 
(Fig. 3C). To test whether levels of αSyn expression correlated with fragmentation phenotype, co-transfected 
neurons were evaluated for mitochondrial size and αSyn intensity (Fig. 3D). Interestingly, low αSyn-expressing 
neurons showed significant fragmentation only in A53T αSyn (Fig. 3D), whereas high αSyn-expressing neurons 
showed significant mitochondrial fragmentation phenotypes in A53T and WT αSyn, but no difference in A30P 
compared with control (GFP, Fig. 3D). These results suggest that different αSyn variants induce a dose-dependent 
mitochondrial fragmentation effect. We then considered whether mitochondrial size correlated with movement, 
given the observed changes in mitochondrial flux and the possibility that smaller mitochondria may be more 
prone to movement. However, no association between mitochondrial size and type of mitochondrial movement 
was observed (Fig. 3E).
To determine whether the effect of A53T αSyn on mitochondrial size was specific to human-derived neurons, 
A53T αSyn was overexpressed in mouse primary neuronal cultures and in human neural stem cells (hNSCs). 
Consistent with our earlier results, co-transfection of mito-GFP and A53T αSyn into mouse hippocampal neu-
rons resulted in a significant reduction in axonal mitochondrial length when compared with control (Fig. 3F). A 
significant decrease in mitochondrial size was also evident in hESC-derived NSCs upon A53T αSyn overexpres-
sion (Figs 3G and S5). Three-dimensional structural reconstruction analysis of mitochondria from transfected 
hNSCs showed that A53T αSyn not only led to a significant size reduction (surface and mean distance to surface), 
but also resulted in alterations in morphology, with mitochondrial shape becoming highly spherical (standard 
deviation of distance, Fig. 3G). Moreover, total mitochondrial mass was unaltered, indicating a compensatory 
increase in mitochondrial number (Fig. 3G). Taken together, these results reveal that A53T αSyn impairs normal 
mitochondrial homeostasis, inducing mitochondrial fragmentation in both neuronal and non-neuronal cells.
Targeted mitochondrial delivery of WT and A53T αSyn, but not A30P, reduces mitochondrial 
size. The location of disease-associated αSyn mutations in the N-terminal domain of αSyn combined with 
the known biophysical interaction of this domain with lipid membranes led us to consider whether A53T αSyn 
might display enhanced membrane binding affinity22, 37. To determine whether αSyn variants differentially asso-
ciate with the mitochondria, subcellular fractions (total, cytosolic, and mitochondrial) were obtained from a 
human neuroblastoma SH-SY5Y cell line transfected with WT, A30P, or A53T αSyn-expressing vectors (Fig. 4A). 
Quantification of αSyn subcellular distribution, calculated as the normalized mitochondrial/cytosolic ratio, 
showed a mild association of WT αSyn with the mitochondria, a reduction of A30P αSyn, and high enrichment 
in A53T αSyn when compared with control (Fig. 4A). Taken together, these results suggest that structural features 
of αSyn variants differentially determine their association with mitochondria and, consequently, the degree of 
mitochondrial defect.
To test whether the effect exerted by αSyn on mitochondrial size requires a direct association of αSyn with 
mitochondrial membranes, we designed a quantitative and time-dependent mitochondrial delivery experiment 
using the FKBP-FRB dimerization system38. WT, A30P, or A53T αSyn subcloned in frame to the FRB domain 
(WT, A30P, or A53T αSyn-FRB) dimerize with the FKBP domain in the presence of a heterodimerizing agent 
(rapalog). GFP and the actin assembly-inducing protein (ActA) fused to FKBP then target the dimerization com-
plex to the OMM (Fig. 4B). GFP-FKBP-ActA mitochondrial localization and αSyn-FRB distribution with or 
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Figure 3. A53T αSyn overexpression reduces mitochondrial size and increases density in human neurons. (A) 
Mean size and density of mitochondria in axons from WT, A30P, or A53T αSyn and mito-GFP co-transfected 
neurons (n = 60 per condition from 10 independent experiments). Scale bar, 5 μm. (B) A53T αSyn-induced 
mitochondrial size reductions were confirmed using immunofluorescent staining against COX-I in transfected 
neurons. Data is represented as mean ± SEM. One-way ANOVA followed by Dunnett’s post-test, *p < 0.05 
(n = 40 from 4 independent experiments). Scale bar, 5 μm. (C) A53T and, to a lesser extent, WT αSyn reduced 
the size of mitochondria. Data presented as median plus interquartile range. (D) Median and percentiles 
corresponding to mitochondrial size categorized by low or high αSyn (above αSyn maximum intensity of 
GFP only-transfected cells) fluorescence intensity on each treatment. Kruskal-Wallis ANOVA for low and 
high αSyn variant compared with control (p < 0.05) (n = 20 neurons). (E) Average mitochondrial size from 
different conditions pooled together for anterograde, stationary, and retrograde mitochondria. Data represented 
as median, 25 and 75 percentiles box, 10 and 90 percentiles whiskers. No significant differences were found. 
Kruskal-Wallis ANOVA (p > 0.05). (n = 2000 mitochondria from 10 independent experiments). (F-G) A53T 
αSyn effects on mitochondrial size are not limited to human neurons. (F) Mouse hippocampal neurons co-
transfected with mito-GFP and empty vector or A53T αSyn. Inset: magnification of the axon. Scale bar, 30 μm, 
inset scale bar, 10 μm. Mean mitochondrial size quantification in axons from A53T αSyn-overexpressing mouse 
neurons compared with control (n = 30 axons from 3 independent experiments). (G) Three-dimensional 
analysis of mitochondrial morphology in human neural stem cells co-transfected with mito-GFP and empty 
vector or A53T αSyn. Color-coded bar shows mitochondrial location in z-axis. Bar graphs show reduction in 
mitochondrial surface, mean distance to surface, and standard deviation (SD) of distance to surface with no 
changes in total mass upon A53T αSyn overexpression (n = 15 cells from 2 independent experiments). Scale 
bar, 20 μm. Data is represented as mean ± SEM. Paired t-test, ***p < 0.001, *p < 0.05. See also Figure S5.
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Figure 4. Differential αSyn association to mitochondrial membrane induces fragmentation. (A) Total, 
cytosolic, and mitochondrial fractions isolated by differential centrifugation of SHSY5Y cells transfected 
with empty, WT, A30P, or A53T αSyn vectors. Tubulin and VDAC1 were used as controls for cytosolic and 
mitochondrial fractions, respectively. Upper panel: αSyn enrichment quantified by mitochondrial/cytosolic 
ratio for control (empty), WT, A30P, or A53T αSyn normalized to the level of αSyn expression. See Figure S8 
for complete overexposed gel. Lower panel: immunoblots showing total protein levels from homogenates and 
quantification of αSyn overexpression levels normalized to WT αSyn. Data is represented as mean ± SEM 
(n = 3 independent experiments). (B) Dimerization scheme showing fusion protein design to deliver αSyn to 
mitochondria. WT, A30P, or A53T αSyn were fused in-frame to FRB motif (αSyn-FRB). A vector driving two 
FKBP domains fused to GFP and an OMM peptide (GFP-FKBP-ActA) that localize to mitochondria was used. 
FRB and FKBP dimerize in the presence of rapalog, inducing αSyn-FRB delivery to the OMM. (C–F) WT and 
A53T, but not A30P αSyn, targeting to the OMM induces mitochondrial fragmentation. (C) Human neurons 
co-transfected with GFP-FKBP-ActA and αSyn-FRB were immunostained for GFP and αSyn to observe the 
αSyn cytosolic localization in 0 nM rapalog and the mitochondrial delivery in the presence of 500 nM rapalog 
for 6 h (Scale bar, 10 μm). (D) Neurons co-transfected with WT or A53T αSyn-FRB plus GFP-FKBP-ActA 
in the presence of 0 or 500 nM rapalog. Inset: axonal magnification. Scale bar, 30 μm; inset, 10 μm. (E) Mean 
mitochondrial size quantification per axon in 0, 200, or 500 nM rapalog for 6 h normalized to empty vector 
control. Linear regression, slopes, and deviation from zero were assessed (WT αSyn-FRB: −0.043, p < 0.001; 
A30P αSyn-FRB: −0.015, p > 0.05; A53T αSyn-FRB: −0.031, p < 0.05). Data is presented as mean ± SEM 
(n = 15 axons per condition from 3 independent experiments). (F) Probability function distribution of total 
pooled mitochondrial size measured in WT, A30P, or A53T αSyn-FRB plus GFP-FKBP-ActA neurons in 0 or 
500 nM rapalog. (n > 300 mitochondria from 3 independent experiments). See also Figure S6.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 5042  | DOI:10.1038/s41598-017-05334-9
without rapalog was assessed (Figs 4C, S6A and B). Two rapalog concentrations (200 and 500 nM) were tested 
to take into account dose-responsive effects. Consistent with our previous results, only A53T αSyn-FRB led to a 
significant reduction in mitochondrial size in the absence of rapalog (Figs 4D,E, and S6C). Rapalog incubation in 
A53T αSyn-FRB resulted in further reductions in the length of axonal mitochondria. Noteworthy, in the presence 
of 500 nM rapalog, WT αSyn-FRB led to a strong and significant reduction in the size of mitochondria similar 
to that seen with A53T αSyn-FRB (Figs 4D,E and S6C). In contrast, no effect on mitochondrial size in A30P 
αSyn-FRB neurons was observed even in the presence of the highest rapalog concentration (Fig. 4D). Consistent 
with this, probability density function analysis of mitochondrial size showed similarities between WT-FRB and 
A30P-FRB αSyn in the absence of rapalog, and between WT-FRB and A53T-FRB αSyn after 6-h incubation with 
500 nM rapalog (Fig. 4F). Our results therefore strongly suggest a biophysical effect of αSyn on axonal mitochon-
drial fragmentation that requires a direct interaction with the OMM in neurons.
αSyn N-terminal domain integrity is necessary for the control of neuronal mitochondrial mor-
phology. To test whether the αSyn N-terminal domain controls the shape and morphology of axonal mito-
chondria, we disrupted the integrity of the α-helix structure in hiPSC. Directed CRISP-R/Cas9 genome editing 
of Craig Venter’s hiPSC line (CV) was performed to generate isogenic lines with disruptions in αSyn conforma-
tion using a specific short guide RNA directed to the exon 2 sequence39 (Fig. 5A). A PCR strategy using αSyn 
exon 2-specific primers was used to screen for positive clones with genomic insertions (Fig. 5A). One putative 
hiPSC-CV CRISPR/Cas9-modified clone (MS06) showed two modified alleles, one with a nucleotide insertion 
that shifted the reading frame, and the other with a net 18-amino acid insertion maintaining the downstream 
frame and giving rise to a higher molecular weight αSyn (Figure S7). αSyn expression in human-derived neurons 
and neural stem cells (NSC) from the MS06 clone revealed an increase of 2 kDa in αSyn molecular weight com-
pared with isogenic controls or mouse hippocampal neurons (Fig. 5B). This confirmed the stable modification of 
αSyn protein with an insertion disrupting the proximity of the two α-helix N-terminal domains but with intact 
downstream sequence. Neuronal differentiation, polarity acquisition, and αSyn expression levels were tested in 
neurons differentiated from clone MS06 and compared with control hiPSC-CV derived neurons (Fig. 5C). After 
14 days in culture, control and CRISP-R/Cas9-modified MS06 neurons were transfected with mito-GFP to assess 
mitochondrial morphology. MS06 neurons were found to display elongated morphologies of axonal mitochon-
dria (Fig. 5E). Quantification of axonal mitochondria showed a significant 35% increase in average mitochondrial 
length with an abnormal distribution in MS06 neurons compared with control hiPSC-CV neurons (Fig. 5G). 
In addition, MS06 neurons contained abnormal mitochondrial morphologies, such as branched and intercon-
nected mitochondria (Fig. 5F). To test whether these changes in mitochondrial morphology were dependent on 
a physiological role for αSyn in mitochondrial homeostasis, we overexpressed A53T αSyn in MS06 neurons. 
Interestingly, A53T αSyn overexpression led to significant reductions in mitochondrial length and distribution 
in MS06 neurons that resulted in even smaller mitochondria than in control hiPSC-CV neurons (Fig. 5E,G). 
To determine whether disruption of αSyn resulted in modification of fusion/fission-related protein levels, e.g., 
mitofusin (MFN) and Dynamin related protein 1 (DRP1), we performed Western blot analysis of CV control 
or MS06 neurons. Quantification of protein levels revealed similar amounts of MFN and DRP1 expression in 
MS06 and control neurons (Fig. 5D), suggesting that mitochondrial elongation in MS06 neurons is promoted 
without changes in expression of mitochondrial quality control proteins. However, this experiment did not rule 
out whether MFN or DRP1 activity may be driving the fragmentation phenotype. Together, these results strongly 
support a physiological role for αSyn in the control of mitochondrial morphology, which could be linked to a 
direct interaction of the N-terminal domain with the mitochondrial membrane.
Discussion
Using a relevant human neuronal cell model, we provide novel evidence supporting the following conclusions: (i) 
αSyn variants have differential effects on mitochondrial transport and size, which is linked to levels of expression 
and mitochondrial localization; (ii) αSyn-dependent mitochondrial fragmentation requires direct interaction 
with the OMM; (iii) disruption of the N-terminal domain induces changes in mitochondrial morphology, sup-
porting a physiological role for αSyn in mitochondrial size regulation; and (iv) this mechanism is not restricted 
to human-derived neuronal cells.
The role of αSyn in mitochondrial function has been the subject of extensive research in the context of neu-
ronal pathology40. Mitochondrial fragmentation has been described in several PD models using different αSyn 
variants, although the specific effect of the different alleles has not been consistent29–31, 41–43. Comprehensive 
studies in relevant human cellular models to test the effect of αSyn mutation, dosage, and localization on mito-
chondrial fragmentation have been lacking. Here, we used human-derived neurons to characterize the effect of 
overexpression of three αSyn variants on axonal mitochondria. A53T αSyn overexpression led to significant 
reductions in axonal mitochondrial size. Milder size reductions were observed upon WT αSyn overexpression, 
but not in A30P overexpression. These differential αSyn effects on mitochondrial size were also dose dependent. 
The significant effect on mitochondrial size observed upon A53T overexpression suggests a gain-of-function 
mechanism, while the lack of effect of A30P, even upon high expression levels, suggests a loss of function. To 
determine whether the observed differences in mitochondrial size were related to a direct association of αSyn 
with the mitochondria, we performed subcellular fractionations in αSyn-overexpressing neuroblastoma cells. 
A53T αSyn localization within the mitochondrial fraction was enhanced compared with WT αSyn, while A30P 
αSyn showed reduced mitochondrial localization. These results suggest that αSyn might exert a functional regu-
lation of mitochondrial morphology that can be modulated by different mutations.
The intrinsic biophysical properties of αSyn allow interaction with lipids, mediating a physiological function 
in synaptic vesicle docking to the plasma membrane44, 45. αSyn association with mitochondria has been proposed 
to depend on the helical conformation of the N-terminal domain of αSyn46. Disease-associated mutations in 
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Figure 5. αSyn α-helix domain disruption increases mitochondrial size in human neurons. (A) Upper panel: 
Scheme of αSyn exon 2 sequence and guide RNA target sequence (red bracket) followed by the PAM sequence (blue) 
for CRISP-R/Cas9-mediated DNA cut. Lower Panel: Genomic PCR screening for insertions or deletions in CV hiPSC 
lines after CRISP-R/Cas9 edition. Two clones, PS06 (smaller size band) and MS06 (larger size band, arrowhead) are 
shown together with WT amplification (arrow). (B) Western blots from homogenates of mouse hippocampus (Hpp) 
and human neural stem cells or differentiated neurons from control or MS06 using two different antibodies against 
αSyn show a higher molecular weight αSyn in MS06 due to the insertion without downstream changes. Monoclonal 
(antigen aa 15–123) and polyclonal (antigen aa 111–131) anti-αSyn. (C) αSyn expression in terminally differentiated 
neurons derived from hiPSC-CV (control) or MS06. Monoclonal or polyclonal αSyn immunofluorescent staining 
in MS06 neurons compared with CV. Scale bar, 50 μm. (D) Western blot from total protein extract from CV and 
MS06 neuron homogenates. Mfn and Drp1 were quantified and normalized to tubulin as control (n = 3 independent 
experiments). (E) Representative images of neurons transfected with mito-GFP for mitochondrial morphology 
analysis of hiPSC-CV, MS06 clone, or MS06 plus A53T αSyn. Inset: magnification of axonal mitochondria. Scale 
bar, 30 μm, inset, 20 μm. (F) Representative images obtained from MS06 differentiated neurons showing abnormal 
elongated, aggregated, and interconnected axonal mitochondria. (G) Significant increase in mean mitochondrial 
size per axon was observed in MS06 neurons when compared to CV-derived neurons, while a reduction in size was 
observed upon A53T αSyn overexpression in MS06 neurons. Data is represented as mean ± SEM (n = 25 axons 
per condition from 2 independent experiments). One-way ANOVA followed by Dunnett’s post-test, *p < 0.05. 
Pooled mitochondria probability density by size distribution plots between MS06 and CV or A53T αSyn transfected 
MS06 and CV. Kolmogorov-Smirnov test performed for each comparison, ***p < 0.001, ****p < 0.0001 (n > 280 
mitochondria per condition from 2 independent experiments).
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αSyn, which are all located within this domain, impact αSyn membrane binding affinity, with the A53T muta-
tion having the highest membrane affinity and A30P having a lower membrane affinity compared with WT 
αSyn22. These differential properties correlate with our results on mitochondrial size and with reports suggesting 
mutation-dependent effects on mitochondrial fragmentation and defects in import machinery47. The association 
of αSyn with the OMM has been initially reported in mouse neurons48. This association seems to be increased 
under artificially-induced low intracellular pH conditions in cell lines overexpressing αSyn variants49. To deter-
mine whether a specific mitochondrial interaction mediated fragmentation, we utilized a dimerization system to 
target the different αSyn variants to the OMM, while maintaining availability of the N-terminal domain to inter-
act freely with membrane molecules. Interestingly, WT and A53T αSyn delivery to the OMM resulted in a rapid 
and dose-dependent mitochondrial fragmentation phenotype, more pronounced than by their overexpression 
alone. In contrast, A30P did not alter mitochondrial size, even at high concentrations of dimerizing agent. Our 
results with A30P are consistent with previous reports that indicate an inability to induce fragmentation, little 
impact on mitochondrial import machinery, and decreased induction of micelle fusion in vitro29, 50. A relation-
ship between membrane curvature and rates of fusion is thought to occur in mitochondria as a result of changing 
lipid and protein composition50, 51. When overexpressed, the enhanced association of αSyn to the OMM either by 
protein-protein or protein-lipid interaction could lead to a decrease in fusion rate29. Consequently, mitochondrial 
fragmentation is favored leading in some cases to mitophagy52, 53. Taken together, these results strongly suggest 
that the effect of αSyn on fragmentation depends on a direct association with the mitochondria.
Given the enriched expression of αSyn in neuronal cells, many endogenous roles have been proposed, 
including control of synaptic vesicle release54, modulation of secretory pathways55, and even vesicle transport 
regulation37. However, whether endogenous αSyn exerts a physiological role in neuronal mitochondria quality 
control has remained unclear. Some clues arise from αSyn knock-out mice, which display a higher resistance 
to mitochondrial neurotoxins used to model PD56. A previous observation that αSyn knockdown suppresses 
stress-induced mitochondrial fission phenotypes also suggests a physiological regulation of mitochondrial 
dynamics9. In addition, the N-terminal domain of αSyn has been implicated in the control of mitochondrial frag-
mentation31, 46. The morphology of mitochondria also depends on recovery of membrane-enriched fusion-fission 
proteins found in mitochondria-associated ER membranes (MAM)57. When overexpressed, α-Syn modulates 
the mitochondria-MAM interaction affecting the transfer of calcium from ER to mitochondria in cell lines58, 59. 
Pathogenic mutations in α-Syn when localized to MAMs reduced the mitochondria-ER interaction while induced 
mitochondrial fragmentation42. The mechanism exerted by α-Syn in MAMs hint at a possible, as yet unexplored 
compartment that might be relevant for understanding the role of α-Syn in PD pathogenesis. To further test the 
hypothesis that α-Syn N-terminal domain interact with membranes to regulate the shape of mitochondria, we 
performed CRISP-R/Cas9-mediated genome editing to disrupt the proximity of the α-helix domains of endoge-
nous αSyn in hiPSC. A shift in mitochondrial morphology towards elongated sizes and branched mitochondria 
was observed in axonal projections of CRISP-R/Cas9-modified human-derived neurons, which was not depend-
ent on changes in MFN or DRP1 proteins levels. In addition, the strong fragmentation elicited by A53T overex-
pression in these modified cells supports a physiological role for the N-terminal domain of αSyn in the regulation 
of mitochondrial dynamics.
The association of αSyn with molecular motors60, 61, and the accumulation of αSyn aggregation bodies sug-
gest that αSyn plays a central role in the induction of axonal transport defects36, 62. Consistent with this view, we 
showed that overexpression of WT or mutated forms of αSyn in human-derived neurons resulted in significant 
defects in anterograde/retrograde mitochondrial flux associated with abnormal mitochondrial distribution in 
axons. Similar dynamic defects have been reported in cell lines and mouse neurons overexpressing WT or A53T 
αSyn overexpression; A30P was not analyzed30. Axonal mitochondrial mobility drives the fusion-fission rates 
that control mitochondria morphology63, and the same counterbalance regulation of mitochondrial transport 
has been suggested when fusion-fission is impaired64. This crosstalk between fusion-fission and axonal flux is 
further influenced by mitochondrial membrane potential, which acts as a sensor of mitochondrial integrity and 
favors retrograde over anterograde transport65. The axonal transport defects observed upon αSyn overexpres-
sion are consistent with the fragmentation phenotype we observed; however, mitochondrial membrane poten-
tial remained unchanged at the time of analysis. This opens the door to further investigation into the effects of 
long-term αSyn overexpression on mitochondrial transport and function.
Many genes associated with PD converge on the mitochondria as a crucial etiological factor in disease 
initiation. PINK1, Parkin, and DJ-1 interact within similar pathways that regulate mitophagy, transport, and 
mitochondrial fusion13, 16, 17. LRRK and VPS35 proteins control mitochondrial morphology by interacting 
with the fission protein DLP1, leading to an increase in mitochondrial fission12, 15. Our findings provide further 
evidence to suggest a physiological role for αSyn in the control of axonal mitochondrial transport and mor-
phology in human-derived neurons, which can be modulated by mutation or gene dosage. The physiological 
and pathological role of αSyn in mitochondrial homeostasis uncovered here may lead to a common pathway 
underlying PD pathogenesis, which is ultimately relevant for understanding neurodegenerative diseases and 
for the future design of preventive or therapeutic strategies for PD.
Methods
Detailed methods can be found in the SI appendix.
Neural differentiation. The human embryonic stem cell (hESC) line Hues9 (H9, WiCell Research 
Institute) and induced pluripotent stem cell line (Craig Venter: CV iPSC SD2010–125, UCSD) were differenti-
ated into polarized and functional neurons following established protocols32 as described in the Supplementary 
Experimental Procedures. pLv-Bobi-CMV-αSyn (WT, A30P, A53T) vectors were introduced into differentiated 
neurons using either lipofectamine transfection or viral transduction at DIV14 for live or fixed experiments.
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Live imaging of fluorescent mitochondria. hESC- or hiPSC-derived neurons were live-imaged in CO2 
and temperature control for fluorescent axonal mitochondria visualization and dynamic tracking of mitochon-
drial movement and morphology as previously described18, 34. Acquisition details and analyses are described in 
the Supplementary Experimental Procedures.
αSyn targeting to mitochondria. WT, A30P, and A53T αSyn-FRB vectors were co-transfected into 
human neurons with GFP-FKBP(x2)-ActA to drive mitochondrial targeting of αSyn in the presence of 200 or 
500 nM rapalog dimerizing agent for 6 h. Transfected and treated neurons were rinsed, fixed, and immunostained 
prior to analysis of mitochondrial morphology.
αSyn N-terminal domain disruption by Crisp-R/Cas9 genomic editing. CrispR/Cas9 disruption of 
the N-terminal domain of αSyn was performed using a guide RNA targeting the SNCA exon 2 sequence between 
both alpha helices of the N-terminal domain of αSyn in iPSCs (CV iPSC). Each clone was tested for insertions or 
deletions by PCR amplification with specific primers flanking the genomic site of the gRNA target. Clone MS06 
was sequenced and selected for analysis of neural differentiation and mitochondrial morphology.
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